These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

171 related articles for article (PubMed ID: 34398356)

  • 21. Physiologically Based Pharmacokinetic (PBPK) Model for Biodistribution of Radiolabeled Peptides in Patients with Neuroendocrine Tumours.
    Gospavic R; Knoll P; Mirzaei S; Popov V
    Asia Ocean J Nucl Med Biol; 2016; 4(2):90-7. PubMed ID: 27408897
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Correlation of Somatostatin Receptor 2 Expression, 68Ga-DOTATATE PET Scan and Octreotide Treatment in Thymic Epithelial Tumors.
    Roden AC; Rakshit S; Johnson GB; Jenkins SM; Mansfield AS
    Front Oncol; 2022; 12():823667. PubMed ID: 35198446
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Influence of lanreotide on uptake of
    Aalbersberg EA; de Wit-van der Veen BJ; Versleijen MWJ; Saveur LJ; Valk GD; Tesselaar MET; Stokkel MPM
    Eur J Nucl Med Mol Imaging; 2019 Mar; 46(3):696-703. PubMed ID: 30097670
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Comparison of the Impact of 68Ga-DOTATATE and 18F-FDG PET/CT on Clinical Management in Patients with Neuroendocrine Tumors.
    Panagiotidis E; Alshammari A; Michopoulou S; Skoura E; Naik K; Maragkoudakis E; Mohmaduvesh M; Al-Harbi M; Belda M; Caplin ME; Toumpanakis C; Bomanji J
    J Nucl Med; 2017 Jan; 58(1):91-96. PubMed ID: 27516446
    [TBL] [Abstract][Full Text] [Related]  

  • 25. 68Ga-DOTATATE PET/CT, 99mTc-HYNIC-octreotide SPECT/CT, and whole-body MR imaging in detection of neuroendocrine tumors: a prospective trial.
    Etchebehere EC; de Oliveira Santos A; Gumz B; Vicente A; Hoff PG; Corradi G; Ichiki WA; de Almeida Filho JG; Cantoni S; Camargo EE; Costa FP
    J Nucl Med; 2014 Oct; 55(10):1598-604. PubMed ID: 25168627
    [TBL] [Abstract][Full Text] [Related]  

  • 26. The diagnostic role of 68Ga-DOTATATE PET/CT in the detection of neuroendocrine tumours.
    Łapińska G; Bryszewska M; Fijołek-Warszewska A; Kozłowicz-Gudzińska I; Ochman P; Sackiewicz-Słaby A
    Nucl Med Rev Cent East Eur; 2011; 14(1):16-20. PubMed ID: 21751167
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Safety and Efficacy of 68Ga-DOTATATE PET/CT for Diagnosis, Staging, and Treatment Management of Neuroendocrine Tumors.
    Deppen SA; Liu E; Blume JD; Clanton J; Shi C; Jones-Jackson LB; Lakhani V; Baum RP; Berlin J; Smith GT; Graham M; Sandler MP; Delbeke D; Walker RC
    J Nucl Med; 2016 May; 57(5):708-14. PubMed ID: 26769865
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Long-Acting Somatostatin Analog Therapy Differentially Alters
    Ayati N; Lee ST; Zakavi R; Pathmaraj K; Al-Qatawna L; Poon A; Scott AM
    J Nucl Med; 2018 Feb; 59(2):223-227. PubMed ID: 28729431
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Biodistribution and radiation dose estimates for
    Krebs S; Pandit-Taskar N; Reidy D; Beattie BJ; Lyashchenko SK; Lewis JS; Bodei L; Weber WA; O'Donoghue JA
    Eur J Nucl Med Mol Imaging; 2019 Mar; 46(3):677-685. PubMed ID: 30374529
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Initial clinical evaluation of indigenous
    Parghane RV; Mitra A; Bannore TU; Rakshit S; Banerjee S; Basu S
    World J Nucl Med; 2021; 20(1):73-81. PubMed ID: 33850492
    [No Abstract]   [Full Text] [Related]  

  • 31. A Practical Guide for the Production and PET/CT Imaging of 68Ga-DOTATATE for Neuroendocrine Tumors in Daily Clinical Practice.
    Aalbersberg EA; Geluk-Jonker MM; Young-Mylvaganan T; de Wit-van der Veen LJ; Stokkel MPM
    J Vis Exp; 2019 Apr; (146):. PubMed ID: 31058910
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Performance of 177Lu-DOTATATE-based peptide receptor radionuclide therapy in metastatic gastroenteropancreatic neuroendocrine tumor: a multiparametric response evaluation correlating with primary tumor site, tumor proliferation index, and dual tracer imaging characteristics.
    Thapa P; Ranade R; Ostwal V; Shrikhande SV; Goel M; Basu S
    Nucl Med Commun; 2016 Oct; 37(10):1030-7. PubMed ID: 27243215
    [TBL] [Abstract][Full Text] [Related]  

  • 33. In Vivo Evaluation of ¹⁸F-SiFAlin-Modified TATE: A Potential Challenge for ⁶⁸Ga-DOTATATE, the Clinical Gold Standard for Somatostatin Receptor Imaging with PET.
    Niedermoser S; Chin J; Wängler C; Kostikov A; Bernard-Gauthier V; Vogler N; Soucy JP; McEwan AJ; Schirrmacher R; Wängler B
    J Nucl Med; 2015 Jul; 56(7):1100-5. PubMed ID: 25977461
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Increased 68Ga-DOTATATE uptake in PET imaging discriminates meningioma and tumor-free tissue.
    Rachinger W; Stoecklein VM; Terpolilli NA; Haug AR; Ertl L; Pöschl J; Schüller U; Schichor C; Thon N; Tonn JC
    J Nucl Med; 2015 Mar; 56(3):347-53. PubMed ID: 25635133
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Clinical utility of
    Parghane RV; Naik C; Talole S; Desmukh A; Chaukar D; Banerjee S; Basu S
    Head Neck; 2020 Mar; 42(3):401-416. PubMed ID: 31755622
    [TBL] [Abstract][Full Text] [Related]  

  • 36. A Prospective Observational Study to Evaluate the Effects of Long-Acting Somatostatin Analogs on
    Gålne A; Almquist H; Almquist M; Hindorf C; Ohlsson T; Nordenström E; Sundlöv A; Trägårdh E
    J Nucl Med; 2019 Dec; 60(12):1717-1723. PubMed ID: 31000584
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Measured human dosimetry of 68Ga-DOTATATE.
    Walker RC; Smith GT; Liu E; Moore B; Clanton J; Stabin M
    J Nucl Med; 2013 Jun; 54(6):855-60. PubMed ID: 23516312
    [TBL] [Abstract][Full Text] [Related]  

  • 38. 68Ga-DOTATATE PET/CT Interobserver Agreement for Neuroendocrine Tumor Assessment: Results of a Prospective Study on 50 Patients.
    Fendler WP; Barrio M; Spick C; Allen-Auerbach M; Ambrosini V; Benz M; Bluemel C; Grewal RK; Lapa C; Miederer M; Nicolas G; Schuster T; Czernin J; Herrmann K
    J Nucl Med; 2017 Feb; 58(2):307-311. PubMed ID: 27539839
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Tumor-to-Blood Ratio for Assessment of Somatostatin Receptor Density in Neuroendocrine Tumors Using
    Ilan E; Velikyan I; Sandström M; Sundin A; Lubberink M
    J Nucl Med; 2020 Feb; 61(2):217-221. PubMed ID: 31302632
    [TBL] [Abstract][Full Text] [Related]  

  • 40.
    Delpassand ES; Ranganathan D; Wagh N; Shafie A; Gaber A; Abbasi A; Kjaer A; Tworowska I; Núñez R
    J Nucl Med; 2020 Jun; 61(6):890-896. PubMed ID: 31924723
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.